Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
In HeLa cell line, FM19G11 (30-300 nM) suppresses HIFα protein [1]. In hypoxic settings, FM19G11 (500 nM) stimulates oligodendrocyte differentiation [1]. In hypoxia GBM-XD, hypoxic T98G, and normoxic T98G cells, FM19G11 (300 nM; 3 days) dramatically reduces the mRNA levels of O6-methylguanine DNA methyltransferase (MGMT) [2]. While FM19G11 did not directly cause apoptosis, M19G11 (300 nM; 3 days) greatly increased temozolomide's (TMZ) pro-apoptotic impact [2].
|
---|---|
ln Vivo |
In severe spinal cord damage (SCI), FM19G11 (intramedullary injection; 1–8 weeks) improves locomotor performance [3]. The expression of RIP, a marker of myelinating oligodendrocytes at the injury site, and GAP43, an axonal growth marker, are both induced by FM19G11 (intramedullary injection; 8 weeks) [3].
|
Cell Assay |
Cell viability assay [2]
Cell Types: GBM-XD and T98G Cell Tested Concentrations: 300 nM Incubation Duration: 3 days Experimental Results: No cytotoxicity per se. Enhanced TMZ cytotoxicity in hypoxic GBM-XD cells, hypoxic T98G cells and normoxic T98G cells. Western Blot Analysis[2] Cell Types: GBM-XD and T98G Cell Tested Concentrations: 300 nM Incubation Duration: 3 days Experimental Results: In hypoxic culture, MGMT expression in both cell lines was Dramatically inhibited. The expression of MGMT was Dramatically down-regulated in T98G cells cultured under normoxia. |
References |
|
Additional Infomation |
3-[[(2,4-dinitrophenyl)-oxomethyl]amino]benzoic acid [2-(4-methylphenyl)-2-oxoethyl] ester is a member of benzamides.
|
Molecular Formula |
C23H17N3O8
|
---|---|
Molecular Weight |
463.402
|
Exact Mass |
463.102
|
CAS # |
329932-55-0
|
PubChem CID |
1730746
|
Appearance |
White to off-white solid powder
|
LogP |
5.533
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
8
|
Rotatable Bond Count |
7
|
Heavy Atom Count |
34
|
Complexity |
784
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
XVUOIWIIQVGWAJ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C23H17N3O8/c1-14-5-7-15(8-6-14)21(27)13-34-23(29)16-3-2-4-17(11-16)24-22(28)19-10-9-18(25(30)31)12-20(19)26(32)33/h2-12H,13H2,1H3,(H,24,28)
|
Chemical Name |
[2-(4-methylphenyl)-2-oxoethyl] 3-[(2,4-dinitrobenzoyl)amino]benzoate
|
Synonyms |
FM19 G11; FM19-G11; FM19G11
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~215.80 mM)
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1580 mL | 10.7898 mL | 21.5796 mL | |
5 mM | 0.4316 mL | 2.1580 mL | 4.3159 mL | |
10 mM | 0.2158 mL | 1.0790 mL | 2.1580 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.